Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

Institut Bergonié631 enrolled

Overview

Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate

Study Type

OBSERVATIONAL

Enrollment

631

Conditions

Cancer Treated With Immune-checkpoint Inhibitors

Interventions

nivolumab monotherapyDRUG

nivolumab monotherapy

nivolumab plus ipilimumabDRUG

nivolumab plus ipilimumab

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

previously untreated advanced melanoma patients.

Locations (1)

Institut Bergonié, Comprehensive Cancer Center

Bordeaux, France

Outcomes

Primary Outcomes

Correlation Between Time to Next Treatment or Death (TNT-D) and Overall Survival (OS)

Correlation between Time to next treatment or death (TNT-D) and overall survival (OS) in previously untreated advanced melanoma patients.

Time frame: 4 years after the start of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.